Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Novavax’s shares traded nearly 20% in pre-market trading at the time of writing. The long-awaited approval for Nuvaxovid restricts its use to adults aged 65 and older. People aged between 12 and ...

US regulators grant full approval to Novavax shot but sharply limit eligibility. New studies on heart risks required, raising concerns over future vaccine access. The US Food and Drug Administration ...

May 19, 2025 – The FDA has approved the Novavax COVID-19 vaccine, a protein-based alternative to mRNA shots, with some limits on who can get it. The vaccine, called Nuvaxovid, is mainly ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

Novavax shares rose in premarket trading after disclosing that the Food and Drug Administration approved an application for Covid-19 treatment Nuvaxovid. Shares rose 10% to $7.41 in premarket ...

Nuvaxovid is a recombinant protein-based COVID ... Jacobs, President and Chief Executive Officer, Novavax. Along with the approval, the FDA also requested Novavax conduct a phase 4 randomized ...

Novavax, Inc. (“Novavax”) announced that FDA approved its Biologics License Application (“BLA”) for Nuvaxovid™ for active ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.

Nuvaxovid™ is the only recombinant protein ... Jacobs, President and Chief Executive Officer, Novavax. "Market research and U.S. CDC statistics indicate that older individuals and those with ...